TITLE:
A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen

CONDITION:
HIV Infections

INTERVENTION:
Ampligen

SUMMARY:

      To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine
      (AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4
      count between 100 and 300 cells/mm3.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  HIV-1 seropositivity.

          -  Absolute number of T4 cells 100-300 cells/mm3.

          -  Given informed consent.

          -  Zidovudine (AZT) therapy for 6 months prior to study entry.

          -  At least one of the listed HIV-related clinical symptoms or opportunistic infections:

          -  weight loss > 10 percent, unexplained diarrhea, unexplained intermittent fever, oral
             candidiasis > 1 month, decreased Karnofsky, oral hairy leukoplakia, chronic fatigue.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Evidence of AIDS.

          -  Intercurrent acute medical disorder.

        Concurrent Medication:

        Excluded:

          -  Chemotherapy for Kaposi's sarcoma (KS).

          -  Aspirin.

          -  Non-steroidal anti-inflammatory drugs.

        Patients with the following are excluded:

          -  Inability to return for treatment and evaluation for 12 months.

          -  Intercurrent acute medical disorder.

          -  Evidence of AIDS.

          -  Receiving chemotherapy for Kaposi's sarcoma (KS).

          -  Unwilling or unable to give informed consent.

        Required:

          -  Zidovudine (AZT).

        Required at least 6 months prior to study entry:

          -  Zidovudine (AZT).

        Active drug abuse.
      
